DE:3D0A Stock Latest News
Company AnnouncementsTelo Genomics Expands Global Studies to Validate Blood-Based Myeloma MRD Test4d ago
Company AnnouncementsTelo Genomics’ Blood-Based TELO-MRD Shows Strong MRD Detection in Multiple Myeloma Comparisons1M ago
Company AnnouncementsTelo Genomics’ Blood-Based Myeloma Assay Outperforms Bone-Marrow MRD Test in Study1M ago- Company AnnouncementsTelo Genomics Advances Blood-Based MRD Testing in Myeloma with New Study and CAP Accreditation6M ago
- Company AnnouncementsTelo Genomics Installs New CEO and Chairman as It Prepares for Pivotal Oncology Milestones7M ago
Company AnnouncementsTelo Genomics Raises $1.39 Million in Final Convertible Debenture Tranche7M ago
Company AnnouncementsTelo Genomics Raises $840,000 in First Tranche of Convertible Debenture Financing8M ago
Company AnnouncementsTelo Genomics Strengthens Finance Team With Appointment of Veteran CFO John Price9M ago
Company AnnouncementsTelo Genomics Seeks Up to $1.2 Million via Convertible Debenture Financing9M ago
Company AnnouncementsTelo Genomics Expands Multiple Myeloma MRD Validation with University of Athens Study10M ago
Company AnnouncementsTelo Genomics Unveils Innovative Myeloma Testing at ASH Meeting10M ago
Company AnnouncementsTelo Genomics Unveils Advanced MRD Technology at Myeloma Summit11M ago
Company AnnouncementsTelo Genomics Unveils Innovative MRD Methodology at Myeloma Society Meeting1y ago
Company AnnouncementsTelo Genomics Engages Hayden IR for Investor Relations Enhancement1y ago
Company AnnouncementsTelo Genomics to Showcase New Strategy at OTCQB Virtual Investor Conference1y ago
Company AnnouncementsTelo Genomics’ MRD Abstract Accepted for Presentation at International Myeloma Society Meeting1y ago
Company AnnouncementsTelo Genomics to Contest Former President’s Lawsuit1y agoCompany AnnouncementsTelo Genomics Launches Clinical Trial for Enhanced Multiple Myeloma Assessment1y ago
